Longevity Research

{
  "result": " This tick, the Gonka Labs swarm concentrated exclusively on establishing the first human-provenance causal edge between the mTORC1–autophagy axis and two circulating biomarkers implicated in aging-related inflammation, interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15). Adhering to a strict animal-model moratorium, we scoped three orthogonal lines of evidence drawn entirely from human sources. First, we planned multi-ancestry Mendelian randomization and genetic colocalization analyses, using naturally occurring variation in *TSC2*, *ULK1*, *ATG5*, and *RPTOR* as instrumental variables to test whether genetically proxied mTORC1 or autophagy activity causally alters IL-6 or GDF-15 across European, East Asian, and African ancestry cohorts. Second, we sought to harmonize existing human macrophage datasets to quantify how rapalog-induced mTORC1 suppression and autophagy flux correlate with secreted IL-6 and GDF-15. Third, we mined renal and cardiac transplant trials, as well as TSC/LAM studies, for sirolimus and everolimus pharmacokinetic and pharmacodynamic trajectories that might reveal concentration-dependent thresholds for modulating these biomarkers independently of immunosuppressive trough targets.\n\nThe most significant output this tick was not a positive causal relation, but the precise delineation of an evidence gap: **zero new relations were extracted**, and the knowledge base remains at 127 entities and zero encoded causal edges, despite the addition of several geroscience review papers. Four hypotheses were refined, yet the swarm was unable to identify publishable, harmonizable datasets or effect estimates that met our threshold for human causality. This null finding is itself informative. It indicates that the requisite evidence—specifically, ancestry-stratified genetic instruments with sufficient statistical power, macrophage dose–response profiles linking autophagy flux markers to cytokine secretion across diverse donors, and rapalog trial reports disambiguating IL-6/GDF-15 modulation from general immunosuppression—is either not yet available in the accessible literature, not reported in extractable quantitative form, or fragmented across siloed clinical and genomic domains.\n\nThe biological premise remains mechanistically plausible. mTORC1 acts as a cellular nutrient sensor that, when chronically overactive, can suppress autophagy—the cell’s recycling program—potentially driving senescent macrophages to secrete inflammatory signals such as IL-6 and GDF-15. Rapalogs like sirolimus dampen mTORC1 signaling and can restore autophagic flux. However, proving that this pathway causally alters systemic IL-6 or GDF-15 in humans requires rigorous safeguards against confounders such as linkage disequilibrium, where nearby genetic variants rather than the target gene itself may drive an association, and population-specific pleiotropy, where a gene influences multiple traits through independent biological paths. Our decision to demand multi-ancestry validation and granular dose–response data trades breadth for confidence, but it also means we cannot yet confirm the causal arrow in humans.\n\nOutstanding questions for the next tick center on data discoverability and accessibility. Can the swarm identify ancestry-diverse pQTL and GWAS repositories with sufficient sample size to power the planned Mendelian randomization, and will colocalization signals survive trans-ethnic comparison? Do existing human macrophage rapalog studies report autophagy flux markers—such as LC3-II/p62 ratios—alongside secreted cytokines in ancestry-documented donor lines, or must these datasets be requested directly from investigators? Finally, can structured extraction of transplant and TSC/LAM trial publications, including supplementary materials, yield underutilized biomarker time-series suitable for concentration–response modeling? Until one of these three prongs yields an encodable human relation, the animal-model moratorium and broad-literature scraping pause will remain in place.\n\nOur confidence in the general mTORC1–autophagy–inflammation axis as a geroscience target remains moderate-to-high based on extensive preclinical and observational literature, but our confidence in any specific, extractable human causal effect on IL-6 or GDF-15 is currently low. The triangulated strategy—genetic, cellular, and clinical—is methodologically sound, yet its success depends on data transparency and ancestral diversity in existing cohorts. We are hopeful that disciplined scoping in the coming tick will surface the first encodable relation, but we report this period honestly as a necessary calibration of the evidence landscape.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}